Bernhardt Zeiher, M.D.  Member of the board of directors for Entrada Therapeutics, Amylyx Pharmaceuticals, and Abeona Therapeutics on Lessons from Leading a Global Development Organization

Bernhardt Zeiher, M.D. Member of the board of directors for Entrada Therapeutics, Amylyx Pharmaceuticals, and Abeona Therapeutics on Lessons from Leading a Global Development Organization

In this episode, I talked with Dr. Bernhardt (Bernie) Zeiher, where he shares key lessons and personal insights from over 25 years in pharmaceutical drug development. Bernie discusses pivotal career moments, including the emotional impact of halting a promising Phase III trial for ARDS, as well as successes such as achieving six drug approvals at Astellas. He emphasizes the critical role of data-driven decision-making, thoughtful hiring, and proactive leadership in managing clinical programs.

Bernie also provides candid reflections on common organizational challenges, particularly the damaging effects of poorly executed reorganizations and layoffs. Throughout the conversation, he underscores the importance of fostering a strong, cohesive team culture, and the necessity of continuous learning and adaptation in pharma leadership.

Bernie also answers some quickfire personal questions: daily coffee habit? Unusual food did Bernie try for the first time recently? Who were the mentors that shaped Bernie’s career the most?

(Find out more in the episode.)

Here’s What You’re In For

  • How data shapes tough go/no-go decisions in drug development.
  • Understanding and avoiding common mistakes during organizational restructuring.
  • Deciding the right moment to transition from part-time consultants to dedicated in-house expertise.

Timestamps

01:10 Career beginnings and transition from pulmonology to pharma

03:35 Emotional setbacks from clinical trial failures

09:00 Factors behind Astellas' multiple drug approvals

12:20 Common pitfalls organizations face during restructuring and reorganizations

16:10 Timing the shift from consultants to dedicated internal clinical leadership

19:40 How Bernie assesses culture fit and hiring red flags

26:00 Quick insights and personal reflections


About Bernie

Dr. Bernhardt Zeiher is a Member of the board of directors for Entrada Therapeutics, Amylyx Pharmaceuticals, and Abeona Therapeutics. Dr. Zeiher is a physician specializing in pulmonary and critical care medicine with over 25 years of experience in drug development. He played a key role in securing approval for CRESEMBA (isavuconazole) for invasive aspergillosis and mucormycosis.

As Head of Development and later Chief Medical Officer at Astellas, led the organization through one of its most productive periods, overseeing six late-phase development products.


Connect with Bernie:



About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.


Connect with me:




Opinions and comments expressed by the guest do not represent the company and are fully their own.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(71)

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Jun 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Mai 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Mai 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Mai 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mar 42min

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

In this episode, I talked with Volker Wacheck, SVP & Head of Clinical Development at Taiho Oncology, where he shared how a PI role in Vienna led him into industry, and why the hardest part wasn’t leav...

9 Mar 29min

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

In this episode, I talked with Dr. Dena Grayson, a physician–scientist with over two decades in biotech drug development. At the time of this recording, she was SVP and Head of Clinical Development at...

24 Feb 31min

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

In this episode, I talked with Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, a Copenhagen-based biotech developing GIPR antagonists in the obesity space.Richard’s career began in ...

26 Jan 35min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
e24-podden
rss-penger-polser-og-politikk
rss-borsmorgen-okonominyhetene
rss-skravla-gar
pengepodden-2
livet-pa-veien-med-jan-erik-larssen
finansredaksjonen
utbytte
okonomiamatorene
rss-pa-konto
tid-er-penger-en-podcast-med-peter-warren
morgenkaffen-med-finansavisen
liberal-halvtime
lederpodden
pengesnakk
rss-impressions-2
stormkast-med-valebrokk-stordalen